ClearBridge Takes Stake in Protagonist Therapeutics Citing Blockbuster Potential
The investor points to two peptide drugs it views as clinically derisked with potential partner launches.
Overview
- In its Q4 2025 investor letter, ClearBridge said it added Protagonist Therapeutics to its Small Cap Growth portfolio.
- ClearBridge described two internally discovered Protagonist drugs as clinically derisked and likely to launch with partners, framing them as high-value assets.
- The thesis centers on an oral version of a widely used injectable mechanism for immune and inflammatory diseases that ClearBridge believes could reach blockbuster sales.
- Insider Monkey reported recent PTGX trading near $102 per share with a market value of about $6.3 billion.
- Hedge fund holders of PTGX rose to 50 portfolios at the end of Q4 from 43 the prior quarter, reflecting growing institutional interest.